Get the Stockscreener App
91.15
1.32%
-1.22
After Hours:
91.15
Guardant Health Inc stock is traded at $91.15, with a volume of 1.65M.
It is down -1.32% in the last 24 hours and down -2.93% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$92.37
Open:
$96.3
24h Volume:
1.65M
Relative Volume:
0.85
Market Cap:
$11.96B
Revenue:
$982.02M
Net Income/Loss:
$-416.28M
P/E Ratio:
-27.50
EPS:
-3.3148
Net Cash Flow:
$-233.07M
1W Performance:
+5.28%
1M Performance:
-2.93%
6M Performance:
+45.49%
1Y Performance:
+114.62%
1-Day Range:
$90.93
$96.30
1-Week Range:
$83.45
$96.30
52-Week Range:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
91.15 | 12.12B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
494.54 | 182.60B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
190.79 | 134.18B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
564.66 | 44.63B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.54 | 32.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.89 | 29.21B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo DrugNews and Statistics - IndexBox
Director at Guardant Health (GH) acquires 155 shares via RSUs - Stock Titan
Quarterly Recap: Can Guardant Health Inc maintain its current growth rate2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
Guardant Health (GH) Gains Momentum on Promising Outlook - GuruFocus
Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026 - Mugglehead Magazine
Why Is Guardant Health (GH) Stock Soaring Today - Yahoo Finance
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health (GH) and Verana Health Announces New Partnership - Insider Monkey
INVESCO Small Cap Equity Fund's Guardant Health Inc(GH) Holding History - GuruFocus
Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors - MSN
The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data - simplywall.st
Guardant Health (GH) Supports Approval of Cancer Treatment in Ja - GuruFocus
Guardant Health Inc (GH) Trading Down 3.96% on Mar 30 - GuruFocus
Guardant Health's AI Data Supports ENHERTU Approval - National Today
Guardant Health's Infinityai real-world evidence supports approval of Enhertu® for previously treated patients with HER2-positive metastatic solid tumors in Japan - MarketScreener
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Business Wire
Liquid Biopsy Market Is Booming Rapidly with Strong Demand By 2033 | Guardant Health Inc., Foundation Medicine Inc. - openPR.com
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook - GlobeNewswire Inc.
(GH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
GH PE Ratio & Valuation, Is GH Overvalued - intellectia.ai
Guardant Health to present new cancer research while stock trades lower amid strong sell signals - Traders Union
Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026News and Statistics - IndexBox
Why Guardant Health (GH) Stock Is Falling Today - Yahoo Finance
Vanguard disaggregates holdings; reports 0% of Guardant Health (GH) - Stock Titan
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Guardant Health wins at Healthcare Asia Medtech Awards 2026 - healthcareasiamagazine.com
Tempus AI Reinforces Market Position With Collaborations in 2026 - TradingView
Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary? - Bitget
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - Lelezard
Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections - Bitget
Guardant Health Manulife Shield Partnership Highlights Asia Growth And Valuation Gap - Yahoo Finance
Guardant Health (GH) director’s RSU vesting adds 264 common shares - Stock Titan
How Guardant’s Shield Blood Test Rollout Through Quest Diagnostics (DGX) Has Changed Its Investment Story - Yahoo Finance
GH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian - TipRanks
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view - MSN
Guardant Health (GH) Partners With Manulife to Launch Shield Multi-Cancer Detection Test in Asia - Insider Monkey
Guardant Health to present 28 abstracts on multiomic cancer research at AACR26 - Traders Union
Guardant Health, Inc. $GH Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) director Tariq Musa sells $30,655 in stock By Investing.com - Investing.com Australia
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock - MarketBeat
Guardant Health (GH) director Tariq Musa sells $30,655 in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 348 company shares - Stock Titan
3 Reasons to Steer Clear of GH and One Alternative Stock Worth Buying - Bitget
Guardant Health Stock Analysis: Price Rise vs. Financial Risks | 2026News and Statistics - IndexBox
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):